REV7: A Small but Mighty Regulator of Genome Maintenance and Cancer Development

January 2025 in “ Frontiers in Oncology ”

Lara R. Maggs, Mitch McVey

Studysummary This review highlights REV7's crucial roles in maintaining genome stability, its implication in several cancers, and its association with poor prognoses and treatment resistance, while also noting that REV7 suppression may improve chemotherapy sensitivity.

Our plain-language summary. Not medical advice or a treatment recommendation. Consult a qualified healthcare professional before changing treatment. Full disclaimer

REV7, a HORMA-domain protein, plays a critical role in maintaining genome stability through its involvement in DNA damage tolerance, cell cycle regulation, and double-strand break repair. It is a key component of polymerase ζ and the shieldin complex, contributing to accurate cell cycle progression and repair pathway choice. REV7's functions are linked to various cancers, such as ovarian, glioma, breast, melanoma, and small-cell lung cancer, where its high expression correlates with poor prognosis and treatment resistance. However, suppressing REV7 may increase sensitivity to chemotherapeutics like cisplatin, highlighting its potential as a therapeutic target. This review explores REV7's diverse roles in genome maintenance and its implications in cancer development and treatment resistance.

View this study on frontiersin.org →

Discuss this study in the Community →

Research cited in this study

2 / 2 results

research MAD2B Acts as a Negative Regulatory Partner of TCF4 on Proliferation in Human Dermal Papilla Cells

8 citations , September 2017 in “Scientific Reports”

This study found that the mitotic arrest deficient protein MAD2B negatively affects TCF4-induced growth and proliferation of dermal papilla cells, which are vital for hair follicle development.

A Randomized, Double-Blind, Placebo-Controlled Trial to Determine the Effectiveness of Botanically Derived Inhibitors of 5-Alpha-Reductase in the Treatment of Androgenetic Alopecia

research A Randomized, Double-Blind, Placebo-Controlled Trial to Determine the Effectiveness of Botanically Derived Inhibitors of 5-Alpha-Reductase in the Treatment of Androgenetic Alopecia

65 citations , April 2002 in “Journal of Alternative and Complementary Medicine”

This study found that 60% of men with mild to moderate androgenetic alopecia showed improvement after treatment with botanically derived 5AR inhibitors, suggesting these compounds may be effective, though larger trials are needed.